Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rein Therapeutics (RNTX) Income from Continuing Operations (2016 - 2025)

Rein Therapeutics (RNTX) has disclosed Income from Continuing Operations for 10 consecutive years, with 5492000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Income from Continuing Operations rose 9.54% to 5492000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 60769000.0, a 105.27% decrease, with the full-year FY2024 number at 65112000.0, down 300.05% from a year prior.
  • Income from Continuing Operations was 5492000.0 for Q3 2025 at Rein Therapeutics, up from 6871000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 1828000.0 in Q3 2023 to a low of 42797000.0 in Q4 2024.
  • A 5-year average of 8055578.95 and a median of 6770000.0 in 2021 define the central range for Income from Continuing Operations.
  • Peak YoY movement for Income from Continuing Operations: soared 76.48% in 2023, then crashed 487.06% in 2024.
  • Rein Therapeutics' Income from Continuing Operations stood at 6816000.0 in 2021, then soared by 31.0% to 4703000.0 in 2022, then crashed by 55.01% to 7290000.0 in 2023, then plummeted by 487.06% to 42797000.0 in 2024, then surged by 87.17% to 5492000.0 in 2025.
  • Per Business Quant, the three most recent readings for RNTX's Income from Continuing Operations are 5492000.0 (Q3 2025), 6871000.0 (Q2 2025), and 5609000.0 (Q1 2025).